Addressing a tangible high unmet medical need with a targeted “cornerstone treatment” of rheumatoid arthritis.
The problem: Rheumatoid arthritis (RA) is a chronic debilitating disease with a high unmet medical need. Methotrexate (MTX) is the established cornerstone treatment of RA in all stages of the disease but has equally well-documented debilitating side effects which affects the vast majority of patients and in turn reduce MTX to a clinically viable treatment for a subsegment of RA patients, only.
The solution: Targeted-MTX has promise to deliver the well understood clinical benefits of the established “cornerstone” treatment(MTX)for RA without the equally documented debilitating side-effects.
The company: We have developed a targeted methotrexate (prodrug) that is designed for targeted release at the site of inflammation where high levels of ROS (reactive oxygen species) are present. MTX delivered as a proprietary molecule directly to the target with a game changing capability to disrupt and revolutionize the present treatment paradigm with a market potential of EUR 3.6 bn in RA in the US, EU and Japan.
This is the first targeted prodrug technology for methotrexate (MTX)
- addressing a high unmet medical need
- a treatment with a higher tolerability and less safety issues
- comparable or better efficacy
- with potential for patients to stay longer on monotherapy / first line therapy
With a program deemed eligible for FDA 505(b)(2) as well as FDA fast track program, we may possibly piggyback on knowledge of MTX for a more abbreviated and less risky drug development program.
Company Details
- Employees
- 6
- Founded
- 2018
- Address
- Ole Maaløes Vej 3, København N,capital Region 2200,denmark
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.rostherapeutics.com/
- Keywords
- Umeå.
- HQ
- København N, Capital Region
Ros Therapeutics Questions
Ros Therapeutics's website is https://www.rostherapeutics.com/
Ros Therapeutics's LinkedIn profile is https://dk.linkedin.com/company/rostherapeutics
Ros Therapeutics has
6 employees.
View email and phone details for 6
employees at Ros Therapeutics.
Ros Therapeutics's industry is
Pharmaceutical Manufacturing
Ros Therapeutics's top competitors are
Lipigon Pharmaceuticals Ab,
Toleranzia Ab,
Fluoguide A/s (Nasdaq: Fluo),
Analyze & Realize Gmbh,
Unibio Laboratoire De Biologie Médicale,
Salient Pharma Aps,
Statumanu Icp Aps,
Loma Therapeutics,
Henlez,
Ondosis.
Ros Therapeutics's categories are Pharmaceutical Manufacturing
Ros Therapeutics's founding year is 2018
